Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Feb 21, 2004 2:38am
308 Views
Post# 7096536

RE: BIOEYE

RE: BIOEYEinteresting that you would make a rare appearance to defend this "forum" of multiple aliases, censorship and other dubious practices. you also seen to conveniently characterize the pumping here as the "positive expression of the known status of the science" right after you say that "until ONC releases information to confirm the status of the science, the stock market is essentially stymied." apparently you are implying that you (like so many of your "friends" here) know better than the market - a lofty position that apparently has endured now low, these many years. all the while, BT & MC maintain their self-imposed "cone of silence" in the onc bunker, perhaps chanting to themselves, "i think i can, i think i can", while two of their largest shareholders quietly dumped every single last one of their onc shares on the market. the 15 patient prostate trial continues, soon to enter its 3rd year, the ph I glio trial the same, while the systemic ph II trial promised for 2002 is only a couple of years late so far & counting. and then we have shareholders underwhelmed by the market reaction to the recent news of FDA approval of erbitux and its implications for onc. but you know better and have for years now, right? perhaps you are unfamiliar with the concept of accountability, but that is what is lacking with onc, and because of that, so is their credibility with the market, and ultimately the share price. oh yea, i forgot - we are way up from the $40M Canadian value the market put on this company when they didn't "know any better". maybe that's why the teachers pension fund & curtis sold?
Bullboard Posts